以下文章来源于东四十条资本 ，作者鲁智高 聚焦股权投资行业人物、事件、数据、研究、政策解读，提供专业视角和深度洞见 | 创投圈有趣的灵魂 将投中网设为"星标⭐"，第一时间收获最新推送 估值超20亿元。 作者丨 鲁智高 来源丨 东四十条资本 一路融到 E 轮后，从苏州起步的丹诺医药来到港交所门前。 在北大校友马振坤的带领下，这家生物科技公司拥有能治疗幽门螺杆菌、人工关节感染、肝性脑病等疾病的在研药物管线，以 及全球首个且目前唯一治疗幽门螺杆菌感染的新分子实体候选药物。 东四十条资本 . 目前，他们即将提交治疗幽门螺杆菌感染的新药上市申请，并已与远大生命科学集团达成该产品的商业合作。这也意味着，自 1982 年发现幽门螺杆菌以来，终于有一款治疗该细菌感染的新分子实体药物要上市了。 丹诺医药能够取得这番亮眼的成绩，离不开众多投资者的大力支持。通和毓承、药明康德、元禾控股、元禾原点、北极光创 投、高特佳投资、中山创投、燕创资本、 Relativity 健康基金、 AMR Action Fund 、 2M 家族基金、 Chao 家族基金等， 都是他们的股东。 北大校友带队，苏州诞生一家明星公司 在创立丹诺医药前，马振坤 ...

出品｜搜狐财经 作为一家创新药企，丹诺医药的核心产品利福特尼唑有望成为全球首个获批上市的针对幽门螺杆菌感染的 新分子实体药物。然而招股书揭示出严峻现实：公司尚无销售收入，2023年以来累计亏损已达3.76亿元， 负债净额高达9.32亿元，账上现金仅剩1.46亿元。 核心产品针对幽门螺杆菌，预计8月底提交上市申请 丹诺医药是一家专注细菌感染与代谢相关疾病领域新药研发的企业，目标适应症包括幽门螺杆菌感染、植 入医疗器械感染、肝硬化肝性脑病和腹泻型肠易激综合征等常见和重大疾病，致力于为患者提供安全有效 的新药产品。 目前，丹诺医药已建立一条由七项创新资产组成的差异化管线，包括三项核心产品：即利福特尼唑（TNP- 2198），是全球首个且唯一治疗幽门螺杆菌感染的新分子实体候选药物；利福喹酮（TNP-2092）注射剂， 一款潜在首创三靶点治疗植入体相关细菌感染的候选药物；及TNP-2092口服制剂，全球首个用于治疗肠道 菌群代谢相关疾病的多靶点候选药物。 其中，最接近商业化的是利福特尼唑。丹诺医药已完成利福特尼唑三联疗法（RTT）对比四联疗法 （BQT）的中国III期头对头临床试验，并计划于2025年8月底前向国家药监 ...

Core Viewpoint - Helicobacter pylori (H. pylori) is a significant public health issue globally, with an infection rate exceeding 50%, and is closely linked to gastric cancer, classified as a Class I carcinogen by the World Health Organization [1][2] Group 1: Market Demand and Growth - The prevalence of H. pylori in China is notably high, with an overall infection rate exceeding 70%, leading to approximately 340,000 new gastric cancer cases annually, accounting for 42% of global cases related to H. pylori [2] - The global market for H. pylori treatment drugs was valued at $5.3 billion in 2019 and is projected to grow at a compound annual growth rate (CAGR) of 6.0%, reaching $6.9 billion by 2024, and further expanding to $10 billion by 2029 [3][4] - The Chinese market for H. pylori treatment drugs was valued at 5.6 billion RMB in 2019, expected to grow to 6.8 billion RMB by 2029, with a CAGR of 4.3% [4] Group 2: Treatment and Innovation - The detection and treatment rates of H. pylori infections in China are expected to rise from 3.0% in 2019 to 3.6% in 2024, and further to 5.8% by 2035 [3] - The American College of Gastroenterology recommends a shift from traditional triple therapy to a quadruple therapy due to rising antibiotic resistance, highlighting the need for innovative treatments [7] - Dano Pharmaceutical's Rifoternizole is the only innovative antibacterial drug currently in development for H. pylori treatment, with plans to submit a New Drug Application (NDA) by August 2025 [7][8] Group 3: Company Overview and Financials - Dano Pharmaceutical, established in 2013, focuses on developing differentiated innovative drug products to address unmet clinical needs in bacterial infections [8] - The company has a pipeline of seven innovative assets, including Rifoternizole, which is designed to overcome antibiotic resistance and improve treatment outcomes [9] - Despite the promising pipeline, Dano Pharmaceutical reported operating losses of approximately 122 million RMB, 77.8 million RMB, and 17.1 million RMB for the years 2023, 2024, and the first three months of 2025, respectively [11][12]

Core Viewpoint - Helicobacter pylori (H. pylori) infection is a significant public health issue globally, with an infection rate exceeding 50%, and is closely linked to gastric cancer, classified as a Group I carcinogen by the World Health Organization [1][2] Industry Overview - H. pylori is associated with various gastric diseases, including gastric ulcers and chronic gastritis, with approximately 80% of gastric cancer cases related to this pathogen [2] - In China, H. pylori infection rates are notably high, with an overall infection rate exceeding 70%, leading to an estimated 340,000 new gastric cancer cases annually, accounting for 42% of global cases related to H. pylori [2] - The global market for H. pylori treatment drugs was valued at $5.3 billion in 2019 and is projected to grow at a compound annual growth rate (CAGR) of 6.0%, reaching $6.9 billion by 2024 and $10 billion by 2029 [3][4] Company Overview - Dano Pharmaceutical (Suzhou) Co., Ltd. is a biotechnology company focused on developing innovative drugs for bacterial infections, with its core product, Rifoternizole (TNP-2198), being the only innovative antibacterial drug in development for H. pylori infection [8][11] - The company has established a differentiated pipeline with seven innovative assets, including TNP-2198, which aims to overcome antibiotic resistance and improve treatment outcomes [9][10] - Dano Pharmaceutical plans to submit a New Drug Application (NDA) for TNP-2198 by the end of August 2025, following successful Phase III clinical trials demonstrating its advantages over existing treatments [10][11] Market Potential - The Chinese market for H. pylori treatment drugs is expected to grow from 5.6 billion RMB in 2019 to 6.8 billion RMB by 2029, with a CAGR of 4.3% [4] - The introduction of TNP-2198 is anticipated to significantly impact the H. pylori treatment market, especially given the rising antibiotic resistance and the shift towards more effective treatment regimens [7][11] Financial Considerations - Dano Pharmaceutical has reported operating losses of approximately 122 million RMB, 77.8 million RMB, and 17.1 million RMB for the years 2023, 2024, and the first three months of 2025, respectively [12] - The company is actively seeking to raise funds through an IPO to support its ongoing research and development efforts, which require substantial financial resources [12][13]

Core Viewpoint - Danuo Pharmaceutical (Suzhou) Co., Ltd. is seeking to go public on the Hong Kong Stock Exchange, focusing on unmet clinical needs in the antibacterial drug sector, particularly targeting Helicobacter pylori infections [1][2]. Company Overview - Danuo Pharmaceutical specializes in the antibacterial drug field, addressing bacterial infections and related diseases [2]. - The company was founded in October 2012 and has undergone several rounds of financing, with a post-money valuation of approximately 2.013 billion RMB after the latest round [2][3]. - The company is managed by Dr. Ma Zhenkun, who has over 30 years of experience in infectious disease drug development [4][5]. Product Pipeline - Danuo has seven drug candidates in development, including three core products: 1. Rifoterinazole (TNP-2198), the first new molecular entity for treating Helicobacter pylori infections [9][11]. 2. Rifoketone (TNP-2092) injection, a potential first-in-class drug for implant-related bacterial infections [13]. 3. TNP-2092 oral formulation, aimed at treating gut microbiota-related metabolic diseases [14]. Market Opportunity - The global market for antibacterial drugs is projected to grow from $45.5 billion in 2024 to $60.3 billion by 2029, with a further increase to $84.3 billion by 2035 [8]. - In China, the antibacterial drug market is expected to decline slightly from 122.9 billion RMB in 2024 to 102.6 billion RMB by 2035 due to volume-based procurement policies [8]. Financial Performance - Danuo Pharmaceutical has not yet generated revenue from product sales, recording net losses of 192 million RMB in 2023 and 146 million RMB in 2024 [16][17]. - The company’s research and development expenses are a significant part of its cost structure, with R&D costs of 108 million RMB in 2023 [18]. Future Prospects - The company plans to submit a new drug application for Rifoterinazole by the end of August 2025, which is crucial for its future revenue generation [12][18].

Core Viewpoint - Danuo Pharmaceutical (Suzhou) Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, focusing on the unmet clinical needs in the field of antibacterial drugs, particularly targeting Helicobacter pylori infections [1][2]. Company Overview - Danuo Pharmaceutical specializes in antibacterial drugs, addressing bacterial infections and related diseases. The company was founded in 2012 and has undergone several rounds of financing, with a post-financing valuation of 2.013 billion RMB as of July 25, 2025 [2][3]. - The company is managed by Dr. Ma Zhenkun, who has over 30 years of experience in infectious disease drug development [4][5]. Product Pipeline - Danuo has seven research pipelines, including three core products: 1. Rifoternizole (TNP-2198), the first and only new molecular entity candidate for treating Helicobacter pylori infections [10]. 2. Rifoqinone (TNP-2092) injection, a potential first-in-class drug for treating implant-associated bacterial infections [13]. 3. TNP-2092 oral formulation, the first multi-target antibacterial candidate for treating gut microbiota-related diseases [15]. Market Opportunity - The global antibacterial drug market is projected to grow from $45.5 billion in 2024 to $60.3 billion by 2029, and further to $84.3 billion by 2035. In China, the market size is expected to decline slightly from 122.9 billion RMB in 2024 to 102.6 billion RMB by 2035 due to volume-based procurement [8]. Financial Performance - Danuo Pharmaceutical has not yet generated revenue from product sales, recording net losses of 192 million RMB in 2023, 146 million RMB in 2024, and 38 million RMB in the first quarter of 2025 [16][17]. - The company's research and development expenses are a significant part of its cost structure, amounting to 108 million RMB in 2023 and 69.8 million RMB in 2024 [19]. Future Prospects - The core product, Rifoternizole, is expected to submit a new drug application by the end of August 2025, indicating a potential pathway to commercialization [12][19].